Fig. 1

Prevalence of cfDNA ESR1 and PIK3CA mutations in patients with metastatic breast cancer. a The sensitivity and specificity of mutation detection in cfDNA compared to paired metastatic tissue samples. b REMARK diagram. c Prevalence of ESR1 mutations in cfDNA among ER + /HER2-metastatic patients. d Prevalence of PIK3CA mutations in cfDNA among ER + /HER2- metastatic patients